All News

Knee.pain_.ice_.injury_0.jpg

Simple Measures are Effective in Knee Osteoarthritis

EurekAlert!

Knee braces, water therapy and exercise are the most promising non-drug therapies for treating knee osteoarthritis, according to a new meta-analysis publishing June 18, 2025 in the open-access journal PLOS One by Yuan Luo of the First People’s Hospital of Neijiang, China.

Read Article
holding hands together support frail

What we need in very early arthritis

David Liew, FRACP

It's easy to think that in our current world that we've done it all for rheumatoid arthritis, that there's nothing left to be done after b/tsDMARDs have become relatively widespread and accessible. If we aren’t satisfied that we’ve done all we can for our RA patients, how can we make their treatment and their lives better?

Read Article
puzzle.RA_.jpg

Persistent Burden in Early RA Despite Disease Control: insights from CareRA Trials

Mrinalini Dey, MD

Advances in the treatment of rheumatoid arthritis, particularly the treat-to-target strategy and the introduction of effective DMARDs, have improved the management of inflammation in RA. However, improved inflammatory markers do not always translate into a resolution of patients’ symptoms or improvements in functional capacity. A recent pooled analysis from the CareRA and CareRA2020 randomized controlled trials shed new light on this dissociation between biological disease control and patient-reported outcomes.

Read Article
nurse,appointment,vitals

Nurse-Led Treat-to-Target Clinics

EurekAlert!

New studies shared at the 2025 annual EULAR congress in Barcelona highlight the benefits that nurse-led care can bring for both patients and healthcare systems.

Read Article
pregnant, pregnancy, mother, fertility

Pregnancy outcomes in autoinflammatory disease

EurekAlert!

To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health.

Read Article
PsA.Hands_.jpg

From Domains to Decisions: Personalizing PsA Care with Data

Jiha Lee, MD

At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; it’s about understanding the unique constellation of domains, comorbidities, and patient factors that shape each clinical decision.

Read Article
Social Determinants of Health in SLE Dr. Mrinalini Dey interviews Dr. Elena Nikiphorou about the topic of social determinants of health in systemic lupus erythematosus, and data being presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/gSFIV8uIuE https://t.co/VpqzVRSwh9

Links:

Dr. John Cush RheumNow ( View Tweet)
Nurse-Led Treat-to-Target Clinics New studies shared at the 2025 annual EULAR congress in Barcelona highlight the benefits that nurse-led care can bring for both patients and healthcare systems. https://t.co/sV8IHhnwbm https://t.co/IrJKvceyez

Links:

Dr. John Cush RheumNow ( View Tweet)
From Domains to Decisions: Personalizing PsA Care with Data At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; https://t.co/tzgE7U4eSj
Dr. John Cush RheumNow ( View Tweet)
Using Combination csDMARDs in PsA Dr. Eric Ruderman shares his insights on abstracts OP0093, OP0106, and POS0106, which discuss the effectiveness of combination csDMARD therapy, long-term outcomes of methotrexate and leflunomide, and a real-world treat-to-target strategy in https://t.co/Pv4YEyYShm
Dr. John Cush RheumNow ( View Tweet)
Social Determinants of Health in SLE SDH, such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases. Understanding how certain factors impact different RMDs is important, https://t.co/Xf2bR7ap5m
Dr. John Cush RheumNow ( View Tweet)
What is the difference between difficult to treat, and treatment-refractory? (see these criteria for PsA) Treatment refractory means that co-morbidities, psychosocial issues and other factors have been managed adequately, but inflammation keeps on going #EULAR2025 @RheumNow https://t.co/Fzpf0eiCWY

Links:

David Liew drdavidliew ( View Tweet)
Joint pain and fatigue are actually the biggest issues for people living with haemochromatosis, but we in rheumatology don’t have organized care for them. A call to action from Patrick Kiely, to do better by these patients #EULAR2025 @RheumNow https://t.co/h3Zvov642L

Links:

David Liew drdavidliew ( View Tweet)
RCT of a digital intervention in RMDs? It was long awaited, and all the lights are green🟢! German national Bechterew-App RCT of App based intervention AXIA, control group was standard of care 200pts 12wks ASAS20 response 51% vs. 9% ASAS40 response rate 23% vs. 3% BASDAI:

Aurelie Najm AurelieRheumo ( View Tweet)

The key changes for the new 2025 EULAR recommendations on RA treatment #EULAR2025 @RheumNow https://t.co/dp5LnoFdpW

Links:

David Liew drdavidliew ( View Tweet)
EULAR PtC for the definition of #TR (Trt Refractory) #Psoriatic_Arthritis #D2M 1️⃣ Failure >= 2 b/tsDMARDs 2️⃣ Problematic 3️⃣ Evidence of persistent disease (inflammation is mandatory) + 4️⃣ Exclude comorbidities, psychosocial factors, failure due to SE/CI #EULAR2025 @RheumNow https://t.co/8nx26mWX3C

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Self-management of rheum disease is ripe for apps, gamification. How well does it work though? This app (Axia) in axSpA was basically as good as a biologic. Maybe you downplay non-pharm management, prob because we don’t do it well. This changes that #EULAR2025 LB0002 @RheumNow https://t.co/sfhEJFsF89

Links:

David Liew drdavidliew ( View Tweet)
#RA #recommendations #update Some recommendations were merged For sure some regions will consider #Combination #csDMARDs or Switch to another 👇🤔 #sulfasalazine #leflunomide Depends on access, pt preference, disease activity/severity #EULAR2025 @RheumNow @eular_org https://t.co/QDPcHhvQiV

Links:

Janet Pope Janetbirdope ( View Tweet)
Presenting our abstract on remote monitoring in rheumatology at #EULAR2025 @RBNHSFT @UniofReading @HenleyBSchool @RheumNow https://t.co/palWjtX3gM

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Leaky pipeline in rheumatology: In a 23-country survey, women left hospital practice earlier—26% at trainee level vs 7% of men. Top reasons? 🚫 Unfair promotion 🚫 Poor communication 🚫 No career path Workplace equity still lags. POS0407 @RheumNow #EULAR2025

Jiha Lee JihaRheum ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×